Kanvas Biosciences (@kanvas), where I'm Chair, has been greenlit to begin trials for its first drug, KAN-004, targeting ICI-induced colitis. KAN-001, a potential blockbuster, that treats ICI-naive and -refractory cancers, to begin later this year.
Remarkable progress for a company founded in 2020 that only began its clinical programs a few years ago. Many congratulations to CEO Matt Cheng, CTO Hao Shi, and Chief Development Officer Lee Swem, and the whole Kanvas team.
